Pharmafile Logo
Pharmafocus logo
Advanced Search

Corcept Therapeutics

Showing 2 posts of 2 posts found.

hsm_mobile_clinical_trial_istock-872676342

Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint

June 9, 2025
Research and Development Corcept Therapeutics, European Network to Cure ALS (ENCALS), Neurology, amyotrophic lateral sclerosis, clinical trial

Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients with amyotrophic lateral sclerosis (ALS), …

News

Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint

April 1, 2025
Research and Development Corcept Therapeutics, Oncology, ovarian cancer, research and development

Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025